Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson s Disease with its NLRP3 Inhibitor, Dapansutrile streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson's granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow.